This just out for those who continue to care about the company..
 
iCo Therapeutics Ranked Number One in Technology & Life Sciences on 2013 TSX Venture 50 
   VANCOUVER, Feb. 14, 2013 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) is pleased to announce it has been named the top ranked company in its class in the TSX Venture Top 50. 
 The Venture 50 is the Exchange's annual list of the strongest performers from five industry sectors. iCo ranked number one among Technology & Life Science companies. Companies are selected based on four equally weighted criteria - return on investment, trading activity, market capitalization growth, and analyst coverage. The results were obtained from data to December 31, 2012. 
 
"Our positive clinical update on our Phase 2 iDEAL study for the treatment of diabetic macular edema was well received by the sector and investment community, which has been demonstrated in our strong and growing performance in 2012," said Andrew Rae, President and CEO of iCo Therapeutics. "We expect to announce primary endpoint data from the iDEAL study before the end of the year and have several other catalyst events in 2013.  We aim to continue our 2012 momentum and hope to make the list again next year." 
 
As the top ranking Technology & Life Science company, iCo has been invited to attend the TSX Venture 50 Spotlight event in April, in Vancouver, with an opportunity to present to an audience comprised of portfolio managers, investment bankers, research analysts and investment advisors.